May 19
American biotech company Moderna has announced positive interim clinical data related to its mRNA-1273 vaccine candidate targeting the novel coronavirus. The positive results come from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 clinical trial. The test involved a total of eight volunteers who received two doses of the experimental vaccine, which will be heading into … Continue reading
Post a Comment